Rethinking Pediatric Gliomas as Developmental Brain Abnormalities

Current Topics in Developmental Biology

Volumn 94, Issue C, 2011, Pages 283-308

  Crouse, Nikkilina R ^a   Dahiya, Sonika ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Astrocytoma; Inherited cancer syndrome; Neurofibromin

Indexed keywords

ANIMAL; BOOK; BRAIN TUMOR; CELL TRANSFORMATION; CHILD; DISEASE COURSE; GENETICS; GLIOMA; HUMAN; PATHOLOGY;

ANIMALS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; DISEASE PROGRESSION; GLIOMA; HUMANS;

EID: 79551481539     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380916-2.00009-7     Document Type: Book

References (126)

1. Alcantara Llaguno S., Chen J., Kwon C.H., Jackson E.L., Li Y., Burns D.K., Alvarez-Buylla A., Parada L.F. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009, 15:45-56.
2. Amankulor N.M., Hambardzumyan D., Pyonteck S.M., Becher O.J., Joyce J.A., Holland E.C. Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J. Neurosci. 2009, 29:10299-10308.
3. Andersen L.B., Ballester R., Marchuk D.A., Chang E., Gutmann D.H., Saulino A.M., Camonis J., Wigler M., Collins F.S. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol. Cell. Biol. 1993, 13:487-495.
4. Bajenaru M.L., Zhu Y., Hedrick N.M., Donahoe J., Parada L.F., Gutmann D.H. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 2002, 22:5100-5113.
5. Bajenaru M.L., Hernandez M.R., Perry A., Zhu Y., Parada L.F., Garbow J.R., Gutmann D.H. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003, 63:8573-8577.
6. Bajenaru M.L., Garbow J.R., Perry A., Hernandez M.R., Gutmann D.H. Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. Ann. Neurol. 2005, 57:119-127.
7. Ballester R., Marchuk D., Boguski M., Saulino A., Letcher R., Wigler M., Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990, 63:851-859.
8. Banati R.B., Gehrmann J., Schubert P., Kreutzberg G.W. Cytotoxicity of microglia. Glia 1993, 7:111-118.
9. Banerjee S., Byrd J.N., Gianino S.M., Harpstrite S.E., Rodriguez F.J., Tuskan R.G., Reilly K.M., Piwnica-Worms D.R., Gutmann D.H. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res. 2010, 70:1356-1366.
10. Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713-715.
11. Bhola P., Banerjee S., Mukherjee J., Balasubramanium A., Arun V., Karim Z., Burrell K., Croul S., Gutmann D.H., Guha A. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int. J. Cancer 2010, 126:563-571.
12. Bollag G., Clapp D.W., Shih S., Adler F., Zhang Y.Y., Thompson P., Lange B.J., Freedman M.H., McCormick F., Jacks T., Shannon K. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 1996, 12:144-148.
13. Brown J.A., Gianino S., Gutmann D.H. Defective cyclic AMP generation underlies the sensitivity of central nervous system neurons to neurofibromatosis-1 heterozygosity. J. Neurosci. 2010, (in press).
14. Burmer G.C., Rabinovitch P.S., Loeb L.A. Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. Environ. Health Perspect. 1991, 93:27-31.
15. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
16. Costa R.M., Yang T., Huynh D.P., Pulst S.M., Viskochil D.H., Silva A.J., Brannan C.I. Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat. Genet. 2001, 27:399-405.
17. Coull J.A., Beggs S., Boudreau D., Boivin D., Tsuda M., Inoue K., Gravel C., Salter M.W., De Koninck Y. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005, 438:1017-1021.
18. Daginakatte G.C., Gutmann D.H. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum. Mol. Genet. 2007, 16:1098-1112.
19. Daginakatte G.C., Gianino S.M., Zhao N.W., Parsadanian A.S., Gutmann D.H. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res. 2008, 68:10358-10366.
20. Dasgupta B., Dugan L.L., Gutmann D.H. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 2003, 23:8949-8954.
21. Dasgupta B., Li W., Perry A., Gutmann D.H. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005, 65:236-245.
22. Dasgupta B., Yi Y., Chen D.Y., Weber J.D., Gutmann D.H. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005, 65:2755-2760.
23. Davoust N., Vuaillat C., Androdias G., Nataf S. From bone marrow to microglia: Barriers and avenues. Trends Immunol. 2008, 29:227-234.
24. DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N., Vass W.C., Lowy D.R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992, 69:265-273.
25. Deshmukh H., Yeh T.H., Yu J., Sharma M.K., Perry A., Leonard J.R., Watson M.A., Gutmann D.H., Nagarajan R. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008, 27:4745-4751.
26. Donovan S., See W., Bonifas J., Stokoe D., Shannon K.M. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2002, 2:507-514.
27. Elkabes S., DiCicco-Bloom E.M., Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J. Neurosci. 1996, 16:2508-2521.
28. Engelman J.A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
29. Flugel A., Labeur M.S., Grasbon-Frodl E.M., Kreutzberg G.W., Graeber M.B. Microglia only weakly present glioma antigen to cytotoxic T cells. Int. J. Dev. Neurosci. 1999, 17:547-556.
30. Forshew T., Tatevossian R.G., Lawson A.R., Ma J., Neale G., Ogunkolade B.W., Jones T.A., Aarum J., Dalton J., Bailey S., Chaplin T., Carter R.L., et al. Activation of the ERK/MAPK pathway: A signature genetic defect in posterior fossa pilocytic astrocytomas. J. Pathol. 2009, 218:172-181.
31. Freeman C.R., Farmer J.P., Montes J. Low-grade astrocytomas in children: Evolving management strategies. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41:979-987.
32. Friedman J.M. Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 1999, 89:1-6.
33. Gibbons J.J., Abraham R.T., Yu K. Mammalian target of rapamycin: Discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 2009, 36(Suppl. 3):S3-S17.
34. Graeber M.B., Scheithauer B.W., Kreutzberg G.W. Microglia in brain tumors. Glia 2002, 40:252-259.
35. Gregorian C., Nakashima J., Dry S.M., Nghiemphu P.L., Smith K.B., Ao Y., Dang J., Lawson G., Mellinghoff I.K., Mischel P.S., Phelps M., Parada L.F., et al. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc. Natl. Acad. Sci. USA 2009, 106:19479-19484.
36. Gressani K.M., Rollins L.A., Leone-Kabler S., Cline J.M., Miller M.S. Induction of mutations in Ki-ras and INK4a in liver tumors of mice exposed in utero to 3-methylcholanthrene. Carcinogenesis 1998, 19:1045-1052.
37. Guillamo J.S., Creange A., Kalifa C., Grill J., Rodriguez D., Doz F., Barbarot S., Zerah M., Sanson M., Bastuji-Garin S., Wolkenstein P. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients. Brain 2003, 126:152-160.
38. Gutmann D.H., Geist R.T., Rose K., Wright D.E. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Dev. Dyn. 1995, 202:302-311.
39. Gutmann D.H., Geist R.T., Wright D.E., Snider W.D. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ. 1995, 6:315-323.
40. Gutmann D.H., Aylsworth A., Carey J.C., Korf B., Marks J., Pyeritz R.E., Rubenstein A., Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51-57.
41. Gutmann D.H., Zhang Y., Hirbe A. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. Ann. Neurol. 1999, 46:777-782.
42. Gutmann D.H., Donahoe J., Brown T., James C.D., Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol. Appl. Neurobiol. 2000, 26:361-367.
43. Gutmann D.H., James C.D., Poyhonen M., Louis D.N., Ferner R., Guha A., Hariharan S., Viskochil D., Perry A. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology 2003, 61:1397-1400.
44. Hawes J.J., Tuskan R.G., Reilly K.M. Nf1 expression is dependent on strain background: Implications for tumor suppressor haploinsufficiency studies. Neurogenetics 2007, 8:121-130.
45. Hegedus B., Banerjee D., Yeh T.H., Rothermich S., Perry A., Rubin J.B., Garbow J.R., Gutmann D.H. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 2008, 68:1520-1528.
46. Hiatt K.K., Ingram D.A., Zhang Y., Bollag G., Clapp D.W. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J. Biol. Chem. 2001, 276:7240-7245.
47. Jacob K., Albrecht S., Sollier C., Faury D., Sader E., Montpetit A., Serre D., Hauser P., Garami M., Bognar L., Hanzely Z., Montes J.L., et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br. J. Cancer 2009, 101:722-733.
48. Janzarik W.G., Kratz C.P., Loges N.T., Olbrich H., Klein C., Schafer T., Scheurlen W., Roggendorf W., Weiller C., Niemeyer C., Korinthenberg R., Pfister S., et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2007, 38:61-63.
49. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA 2005, 102:8573-8578.
50. Johannessen C.M., Johnson B.W., Williams S.M., Chan A.W., Reczek E.E., Lynch R.C., Rioth M.J., McClatchey A., Ryeom S., Cichowski K. TORC1 is essential for NF1-associated malignancies. Curr. Biol. 2008, 18:56-62.
51. Jones D.T., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., Ichimura K., Collins V.P. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008, 68:8673-8677.
52. Khalaf W.F., Yang F.C., Chen S., White H., Bessler W., Ingram D.A., Clapp D.W. K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/- mast cells. J. Immunol. 2007, 178:2527-2534.
53. Kim H.A., Rosenbaum T., Marchionni M.A., Ratner N., DeClue J.E. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 1995, 11:325-335.
54. Kluwe L., Hagel C., Tatagiba M., Thomas S., Stavrou D., Ostertag H., von Deimling A., Mautner V.F. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 2001, 60:917-920.
55. Knudson A.G. Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971, 68:820-823.
56. Kostianovsky A.M., Maier L.M., Anderson R.C., Bruce J.N., Anderson D.E. Astrocytic regulation of human monocytic/microglial activation. J. Immunol. 2008, 181:5425-5432.
57. Kunkel P., Muller S., Schirmacher P., Stavrou D., Fillbrandt R., Westphal M., Lamszus K. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro. Oncol. 2001, 3:82-88.
58. Lafuente J.V., Adan B., Alkiza K., Garibi J.M., Rossi M., Cruz-Sanchez F.F. Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J. Mol. Neurosci. 1999, 13:177-185.
59. Lai J.P., Zhan G.X., Campbell D.E., Douglas S.D., Ho W.Z. Detection of substance P and its receptor in human fetal microglia. Neuroscience 2000, 101:1137-1144.
60. Legius E., Dierick H., Wu R., Hall B.K., Marynen P., Cassiman J.J., Glover T.W. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosom. Cancer 1994, 10:250-255.
61. Li J., Perry A., James C.D., Gutmann D.H. Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology 2001, 56:885-890.
62. Li F., Munchhof A.M., White H.A., Mead L.E., Krier T.R., Fenoglio A., Chen S., Wu X., Cai S., Yang F.C., Ingram D.A. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum. Mol. Genet. 2006, 15:1921-1930.
63. Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007, 67:5064-5066.
64. Listernick R., Darling C., Greenwald M., Strauss L., Charrow J. Optic pathway tumors in children: The effect of neurofibromatosis type 1 on clinical manifestations and natural history. J. Pediatr. 1995, 127:718-722.
65. Listernick R., Ferner R.E., Liu G.T., Gutmann D.H. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann. Neurol. 2007, 61:189-198.
66. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
67. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
68. Luber-Narod J., Kage R., Leeman S.E. Substance P enhances the secretion of tumor necrosis factor-alpha from neuroglial cells stimulated with lipopolysaccharide. J. Immunol. 1994, 152:819-824.
69. MacConaill L.E., Campbell C.D., Kehoe S.M., Bass A.J., Hatton C., Niu L., Davis M., Yao K., Hanna M., Mondal C., Luongo L., Emery C.M., et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009, 4:e7887.
70. Mancini F., Moretti F. Mitochondrial MDM4 (MDMX): An unpredicted role in the p53-mediated intrinsic apoptotic pathway. Cell Cycle 2009, 8:3854-3859.
71. Marchuk D.A., Saulino A.M., Tavakkol R., Swaroop M., Wallace M.R., Andersen L.B., Mitchell A.L., Gutmann D.H., Boguski M., Collins F.S. cDNA cloning of the type 1 neurofibromatosis gene: Complete sequence of the NF1 gene product. Genomics 1991, 11:931-940.
72. Marin-Teva J.L., Dusart I., Colin C., Gervais A., van Rooijen N., Mallat M. Microglia promote the death of developing Purkinje cells. Neuron 2004, 41:535-547.
73. Markovic D.S., Vinnakota K., Chirasani S., Synowitz M., Raguet H., Stock K., Sliwa M., Lehmann S., Kalin R., van Rooijen N., Holmbeck K., Heppner F.L., et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. USA 2009, 106:12530-12535.
74. Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990, 63:843-849.
75. Martin F.C., Anton P.A., Gornbein J.A., Shanahan F., Merrill J.E. Production of interleukin-1 by microglia in response to substance P: Role for a non-classical NK-1 receptor. J. Neuroimmunol. 1993, 42:53-60.
76. McDaniel A.S., Allen J.D., Park S.J., Jaffer Z.M., Michels E.G., Burgin S.J., Chen S., Bessler W.K., Hofmann C., Ingram D.A., Chernoff J., Clapp D.W. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood 2008, 112:4646-4654.
77. Morgan D., Gordon M.N., Tan J., Wilcock D., Rojiani A.M. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for Alzheimer therapeutics. J. Neuropathol. Exp. Neurol. 2005, 64:743-753.
78. Parney I.F., Waldron J.S., Parsa A.T. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Lab. Invest. J. Neurosurg. 2009, 110:572-582.
79. Perrone F., Da Riva L., Orsenigo M., Losa M., Jocolle G., Millefanti C., Pastore E., Gronchi A., Pierotti M.A., Pilotti S. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 2009, 11:725-736.
80. Piecha D., Muratoglu S., Morgelin M., Hauser N., Studer D., Kiss I., Paulsson M., Deak F. Matrilin-2, a large, oligomeric matrix protein, is expressed by a great variety of cells and forms fibrillar networks. J. Biol. Chem. 1999, 274:13353-13361.
81. Platten M., Kretz A., Naumann U., Aulwurm S., Egashira K., Isenmann S., Weller M. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann. Neurol. 2003, 54:388-392.
82. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
83. Puca R., Nardinocchi L., Sacchi A., Rechavi G., Givol D., D'Orazi G. HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol. Cancer 2009, 8:85.
84. Rasley A., Bost K.L., Olson J.K., Miller S.D., Marriott I. Expression of functional NK-1 receptors in murine microglia. Glia 2002, 37:258-267.
85. Reilly K.M., Loisel D.A., Bronson R.T., McLaughlin M.E., Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet. 2000, 26:109-113.
86. Reilly K.M., Tuskan R.G., Christy E., Loisel D.A., Ledger J., Bronson R.T., Smith C.D., Tsang S., Munroe D.J., Jacks T. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc. Natl. Acad. Sci. USA 2004, 101:13008-13013.
87. Reish O., Orlovski A., Mashevitz M., Sher C., Libman V., Rosenblat M., Avivi L. Modified allelic replication in lymphocytes of patients with neurofibromatosis type 1. Cancer Genet. Cytogenet. 2003, 143:133-139.
88. Robinson J.P., VanBrocklin M.W., Guilbeault A.R., Signorelli D.L., Brandner S., Holmen S.L. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene 2010, 29:335-344.
89. Roumier A., Bechade C., Poncer J.C., Smalla K.H., Tomasello E., Vivier E., Gundelfinger E.D., Triller A., Bessis A. Impaired synaptic function in the microglial KARAP/DAP12-deficient mouse. J. Neurosci. 2004, 24:11421-11428.
90. Sandsmark D.K., Zhang H., Hegedus B., Pelletier C.L., Weber J.D., Gutmann D.H. Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res. 2007, 67:4790-4799.
91. Sanoudou D., Tingby O., Ferguson-Smith M.A., Collins V.P., Coleman N. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br. J. Cancer 2000, 82:1218-1222.
92. Schiffman J.D., Hodgson J.G., VandenBerg S.R., Flaherty P., Polley M.Y., Yu M., Fisher P.G., Rowitch D.H., Ford J.M., Berger M.S., Ji H., Gutmann D.H., et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010, 70:512-519.
93. Sharma M.K., Zehnbauer B.A., Watson M.A., Gutmann D.H. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005, 65:1335-1336.
94. Sharma M.K., Watson M.A., Lyman M., Perry A., Aldape K.D., Deak F., Gutmann D.H. Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology 2006, 66:127-130.
95. Sharma M.K., Mansur D.B., Reifenberger G., Perry A., Leonard J.R., Aldape K.D., Albin M.G., Emnett R.J., Loeser S., Watson M.A., Nagarajan R., Gutmann D.H. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res. 2007, 67:890-900.
96. Sievert A.J., Fisher M.J. Pediatric low-grade gliomas. J. Child Neurol. 2009, 24:1397-1408.
97. Simmons G.W., Pong W.W., Emnett R.J., White C.R., Gianino S.M., Rodriguez F.J., Gutmann D.H. Neurofibromatosis-1 heterozygosity increases microglia in a spatially- and temporally-restricted pattern relevant to mouse optic glioma formation and growth. J. Neuropathol. Exp. Neurol. 2011, (in press).
98. Struve J., Maher P.C., Li Y.Q., Kinney S., Fehlings M.G., Kuntz C.T., Sherman L.S. Disruption of the hyaluronan-based extracellular matrix in spinal cord promotes astrocyte proliferation. Glia 2005, 52:16-24.
99. Sun T., Gianino S., Jackson E., Piwnica-Worms D.R., Gutmann D.H., Rubin J.B. CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. J. Neuroimmunol. 2010, (in press).
100. Surawicz T.S., Davis F., Freels S., Laws E.R., Menck H.R. Brain tumor survival: Results from the National Cancer Data Base. J. Neurooncol. 1998, 40:151-160.
101. Surawicz T.S., McCarthy B.J., Kupelian V., Jukich P.J., Bruner J.M., Davis F.G. Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1999, 1:14-25.
102. Taylor M.D., Poppleton H., Fuller C., Su X., Liu Y., Jensen P., Magdaleno S., Dalton J., Calabrese C., Board J., Macdonald T., Rutka J., Guha A., Gajjar A., Curran T., Gilbertson R.J. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005, 8:323-335.
103. Tong J., Hannan F., Zhu Y., Bernards A., Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 2002, 5:95-96.
104. Tsai J.C., Goldman C.K., Gillespie G.Y. Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg. 1995, 82:864-873.
105. Verdijk R.M., den Bakker M.A., Dubbink H.J., Hop W.C., Dinjens W.N., Kros J.M. TP53 mutation analysis of malignant peripheral nerve sheath tumors. J. Neuropathol. Exp. Neurol. 2010, 69:16-26.
106. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2009, 17:98-110.
107. Viskochil D., Buchberg A.M., Xu G., Cawthon R.M., Stevens J., Wolff R.K., Culver M., Carey J.C., Copeland N.G., Jenkins N.A., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62:187-192.
108. Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., et al. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181-186.
109. Warrington N.M., Woerner B.M., Daginakatte G.C., Dasgupta B., Perry A., Gutmann D.H., Rubin J.B. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 2007, 67:8588-8595.
110. Warrington N.M., Gianino S.M., Jackson E., Goldhoff P., Garbow J.R., Piwnica-Worms D., Gutmann D.H., Rubin J.B. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res. 2010, 70:5717-5727.
111. Watters J.J., Schartner J.M., Badie B. Microglia function in brain tumors. J. Neurosci. Res. 2005, 81:447-455.
112. Weissenberger J., Loeffler S., Kappeler A., Kopf M., Lukes A., Afanasieva T.A., Aguzzi A., Weis J. IL-6 is required for glioma development in a mouse model. Oncogene 2004, 23:3308-3316.
113. Wesolowska A., Kwiatkowska A., Slomnicki L., Dembinski M., Master A., Sliwa M., Franciszkiewicz K., Chouaib S., Kaminska B. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-An inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 2008, 27:918-930.
114. White F.V., Anthony D.C., Yunis E.J., Tarbell N.J., Scott R.M., Schofield D.E. Nonrandom chromosomal gains in pilocytic astrocytomas of childhood. Hum. Pathol. 1995, 26:979-986.
115. Wimmer K., Eckart M., Meyer-Puttlitz B., Fonatsch C., Pietsch T. Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 2002, 61:896-902.
116. Xu G.F., Lin B., Tanaka K., Dunn D., Wood D., Gesteland R., White R., Weiss R., Tamanoi F. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 1990, 63:835-841.
117. Yamada T., Tsubouchi H., Daikuhara Y., Prat M., Comoglio P.M., McGeer P.L., McGeer E.G. Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues. Brain Res. 1994, 637:308-312.
118. Yang F.C., Chen S., Robling A.G., Yu X., Nebesio T.D., Yan J., Morgan T., Li X., Yuan J., Hock J., Ingram D.A., Clapp D.W. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J. Clin. Invest. 2006, 116:2880-2891.
119. Yang F.C., Ingram D.A., Chen S., Zhu Y., Yuan J., Li X., Yang X., Knowles S., Horn W., Li Y., Zhang S., Yang Y., et al. Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell 2008, 135:437-448.
120. Yang I., Han S.J., Kaur G., Crane C., Parsa A.T. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci. 2010, 17, 6-10.
121. Yeh T.H., Lee da Y., Gianino S.M., Gutmann D.H. Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia 2009, 57:1239-1249.
122. Yu J., Deshmukh H., Gutmann R.J., Emnett R.J., Rodriguez F.J., Watson M.A., Nagarajan R., Gutmann D.H. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 2009, 73:1526-1531.
123. Zattara-Cannoni H., Gambarelli D., Lena G., Dufour H., Choux M., Grisoli F., Vagner-Capodano A.M. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet. Cytogenet. 1998, 104:157-160.
124. Zhu Y., Ghosh P., Charnay P., Burns D.K., Parada L.F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002, 296:920-922.
125. Zhu Y., Harada T., Liu L., Lush M.E., Guignard F., Harada C., Burns D.K., Bajenaru M.L., Gutmann D.H., Parada L.F. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005, 132:5577-5588.
126. Zohrabian V.M., Nandu H., Gulati N., Khitrov G., Zhao C., Mohan A., Demattia J., Braun A., Das K., Murali R., Jhanwar-Uniyal M. Gene expression profiling of metastatic brain cancer. Oncol. Rep. 2007, 18:321-328.